What is the evidence and role of neoadjuvant CDK4/6 inhibitors in hormone‑positive breast cancer?

Neoadjuvant CDK4/6 Inhibitors in Hormone-Positive Breast Cancer: Current Evidence and Role

Neoadjuvant CDK4/6 inhibitors are NOT currently recommended as standard of care for hormone receptor-positive, HER2-negative early breast cancer, as they remain investigational in this setting with no established role outside of clinical trials.

Current Regulatory Status and Guidelines

The NCCN 2024 guidelines 1 explicitly address CDK4/6 inhibitors only in the adjuvant setting, not neoadjuvant. The guidelines establish:

• Abemaciclib (2 years) combined with endocrine therapy is a Category 1, preferred option for high-risk disease (≥4 positive nodes OR 1-3 positive nodes with grade 3 or size ≥5 cm)
• Ribociclib (3 years) shows benefit in stage II-III disease, though additional follow-up is needed
• Palbociclib showed no benefit in adjuvant trials

Critically, no guideline recommends neoadjuvant CDK4/6 inhibitors as standard practice 1.

Evidence from Neoadjuvant Studies

What the Research Shows

The neoadjuvant data reveals a fundamental disconnect between biological activity and clinical benefit:

Biological Activity (Ki67 Suppression):

• CDK4/6 inhibitors plus endocrine therapy achieve significantly higher rates of complete cell cycle arrest (CCCA, defined as Ki67 <2.7%) compared to endocrine therapy alone 2, 3
• Meta-analysis shows OR = 7.91 (95% CI: 4.81-13.03) for achieving CCCA 3
• All three CDK4/6 inhibitors (ribociclib, palbociclib, abemaciclib) demonstrate this effect 3

Clinical Outcomes (What Actually Matters):

• No significant improvement in pathological complete response (pCR) rates: OR = 0.34 (95% CI: 0.04-2.85, p=0.318) 3
• pCR rates remain extremely low (typically <5%) with endocrine-based neoadjuvant therapy, regardless of CDK4/6 inhibitor addition 4, 5
• No demonstrated improvement in long-term survival outcomes 4, 2

The Critical Problem

Ki67 suppression does not translate to meaningful pathological response in the neoadjuvant setting. While Ki67 has been validated as a surrogate endpoint for comparing different endocrine therapies 6, it has not been validated as a surrogate for overall survival when adding targeted agents to endocrine therapy in early breast cancer.

Comparison to Standard Neoadjuvant Chemotherapy

When neoadjuvant CDK4/6 inhibitors plus endocrine therapy are compared to standard chemotherapy 3:

• Similar pCR rates: OR = 0.50 (95% CI: 0.12-2.07, p=0.342)
• Lower grade 3-4 toxicity: OR = 0.50 (95% CI: 0.29-0.87, p=0.015)
• Similar residual cancer burden outcomes

However, this apparent equivalence is misleading because:

1. Chemotherapy achieves higher pCR rates in HR+/HER2- disease than endocrine therapy
2. The studies comparing these approaches are small and not adequately powered
3. Long-term survival data are absent

Toxicity Considerations

Adding CDK4/6 inhibitors to neoadjuvant endocrine therapy significantly increases toxicity 2, 3:

• All-grade adverse events: OR = 9.10 (95% CI: 2.39-34.58)
• Grade 3-4 adverse events: OR = 12.24 (95% CI: 4.17-35.88)
• Common toxicities include neutropenia, diarrhea (especially with abemaciclib), and fatigue

Clinical Algorithm: When to Consider Neoadjuvant Therapy

For Hormone-Positive, HER2-Negative Breast Cancer:

1. Assess Need for Tumor Downstaging:

• If breast-conserving surgery is already feasible → Proceed directly to surgery, consider adjuvant CDK4/6 inhibitors if high-risk criteria met
• If downstaging needed for surgical options → Continue to step 2

2. Determine Optimal Neoadjuvant Approach:

Choose Neoadjuvant Chemotherapy if:

• Patient is premenopausal with high-risk features (node-positive, high grade)
• Rapid tumor response needed
• Tumor has high proliferation (high Ki67) suggesting chemosensitivity
• Goal is to achieve pCR for prognostic information

Choose Neoadjuvant Endocrine Therapy if:

• Patient is postmenopausal
• Tumor is strongly ER-positive (>50%)
• Low proliferation (low Ki67)
• Patient has contraindications to chemotherapy
• Do NOT routinely add CDK4/6 inhibitors - reserve for clinical trials

3. Duration of Neoadjuvant Endocrine Therapy:

• Minimum 4-6 months for adequate assessment 7
• Aromatase inhibitors preferred over tamoxifen in postmenopausal women 7

Critical Pitfalls to Avoid

1. Do not use neoadjuvant CDK4/6 inhibitors based solely on Ki67 suppression data - this is a pharmacodynamic marker, not a validated clinical endpoint for this indication

2. Do not extrapolate from metastatic disease success - the biology of micrometastatic disease differs fundamentally from established metastatic disease 8

3. Do not confuse adjuvant with neoadjuvant evidence - adjuvant abemaciclib and ribociclib have demonstrated invasive disease-free survival benefits 9, but this does not validate neoadjuvant use

4. Recognize the adjuvant CDK4/6 inhibitor controversy - even in the adjuvant setting where benefits are seen, concerns exist regarding trial design, lack of overall survival benefit, informative censoring, and potential for inducing resistance 10

Current Investigational Status

Multiple ongoing trials are evaluating neoadjuvant CDK4/6 inhibitors 4, 5:

• Various combinations with endocrine therapy
• Different treatment durations
• Biomarker-selected populations
• Window-of-opportunity studies

These remain investigational and should not guide current practice.

Bottom Line for Clinical Practice

For patients requiring neoadjuvant therapy for HR+/HER2- breast cancer:

• Standard chemotherapy remains the preferred approach when rapid tumor response and downstaging are needed
• Neoadjuvant endocrine therapy alone (aromatase inhibitor in postmenopausal women) is appropriate for select patients with contraindications to chemotherapy or strongly hormone-dependent tumors
• CDK4/6 inhibitors should be reserved for the adjuvant setting in high-risk patients meeting established criteria (≥4 positive nodes or 1-3 nodes with high-risk features) 1, 9
• Enrollment in clinical trials is the only appropriate context for neoadjuvant CDK4/6 inhibitor use

The disconnect between biological activity (Ki67 suppression) and clinical benefit (pCR, survival) in the neoadjuvant setting underscores that not all pharmacodynamic effects translate to meaningful patient outcomes. Until trials demonstrate improvements in pathological response rates or long-term survival, neoadjuvant CDK4/6 inhibitors remain an unproven strategy that adds toxicity and cost without established benefit.